A Novel Human Antibody, HF, against HER2/erb-B2 Obtained by a Computer-Aided Antibody Design Method
Fully human antibodies have minimal immunogenicity and safety profiles. At present, most potential antibody drugs in clinical trials are humanized or fully human. Human antibodies are mostly generated using the phage display method (in vitro) or by transgenic mice (in vivo); other methods include B...
Main Authors: | Chunxia Qiao, Ming Lv, Xinying Li, Xiaoling Lang, Shouqin Lv, Mian Long, Yan Li, Shusheng Geng, Zhou Lin, Beifen Shen, Jiannan Feng |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-11-01
|
Series: | Engineering |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2095809921003829 |
Similar Items
-
Association between serum HER2/ErbB2 levels and coronary artery disease: a case–control study
by: Wen Jian, et al.
Published: (2020-03-01) -
The Mysterious Ways of ErbB2/HER2 Trafficking
by: Vibeke Bertelsen, et al.
Published: (2014-08-01) -
Arg9 facilitates the translocation and downstream signal inhibition of an anti-HER2 single chain antibody
by: Hu Yi, et al.
Published: (2012-07-01) -
Challenges and future of HER2-positive gastric cancer therapy
by: Chenzhe Ma, et al.
Published: (2023-01-01) -
Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer
by: Soojung Lee, et al.
Published: (2023-04-01)